Merck acquires Terns Pharma

Merck & Co., a prominent player in the pharmaceutical industry, has reached an agreement to acquire Terns Pharma for $6.7 billion. This move signals Merck's continued push to bolster its pipeline with innovative therapies, particularly within the competitive healthcare sector.

Under the terms of the transaction, Merck will integrate Terns Pharma, a clinical-stage biopharmaceutical company focused on developing treatments for chronic liver diseases. While detailed terms of the acquisition are pending, the deal is valued at $6.7 billion. News of the acquisition was first reported on March 25, 2026, by Reuters. It is important to note that the consummation of the transaction is still pending, with further regulatory approval and customary closing conditions to be met.

This acquisition underscores Merck's strategy to expand its portfolio in therapeutic areas with significant potential. By acquiring Terns Pharma, Merck aims to leverage its research capabilities to accelerate the development of Terns’ pipeline, particularly targeting nonalcoholic steatohepatitis (NASH) and other liver diseases. This strategic move is expected to enhance Merck's standing in the treatment of chronic diseases, an area where innovation is critical as the healthcare landscape rapidly evolves.

In the broader market context, Merck's acquisition of Terns Pharma can potentially reconfigure the competitive dynamics within the biopharmaceutical field. Terns' innovative approach in drug development could give Merck an edge over competitors focusing on similar therapeutic areas. The transaction also highlights the ongoing trend of major pharmaceutical companies acquiring smaller biotechs to supplement their drug offerings amidst industry pressure for new treatments.

As Merck moves towards finalizing this acquisition, investors and industry analysts will be watching closely for further details about the integration process and the regulatory pathway. Monitoring the developments around this acquisition will be crucial as the market assesses its impact on Merck's operational strategy and financial performance in the coming quarters.